Scalable Synthesis of 6-Chloro-1H-pyrazolo[3,4-b]pyrazine via a Continuous Flow Formylation/Hydrazine Cyclization Cascade

Abstract

Herein, we describe the development of two continuous manufacturing processes for the synthesis of 6-chloro-1H-pyrazolo[3,4-b]pyrazine, which is a key intermediate en route to the SHP2 inhibitor GDC-1971 (migoprotafib). The reaction sequence starts with a plug-flow metalation/formylation of readily available 2,6-dichloropyrazine using i-Pr2NMgCl·LiCl (MgDA) as the base, whereupon the resulting unstable heteroaryl aldehyde intermediate is isolated as its easier-to-handle and bench-stable bisulfite adduct. The ensuing cyclization step to the pyrazolopyrazine product necessitates the use of excess amounts of hydrazine reagent, and involves the accumulation of highly energetic, nitrogen-rich intermediates. A continuous stirred-tank reactor (CSTR) process was engineered to address the associated safety concerns while accommodating for the heterogeneity of the reaction mixture. These two safe and robust continuous processes have been demonstrated on multikilogram scale, and serve as enabling contributions toward large-scale manufacturing of GDC-1971.

Early-Stage Flow Process Development of a Key Intermediate toward PF-07265807, an AXL-MER Inhibitor Oncology Candidate

“…The use of hydrazine in flow has been previously reported in several cases, − primarily due to hydrazine enabling the most efficient means for each specific transformation, and flow providing the opportunity for risk mitigation as well as process intensification. In this work, the rationale for an increased safety profile for aqueous hydrazine in flow was that it minimizes the overall volume of aqueous hydrazine in a reactor at any given time and eliminates the accumulation of vapors in the headspace due to the reduced dimensions and inherent lack of headspace in plug flow reactors (PFRs).…”